Innovative delivery systems for paediatric medicines technology landscape
Unitaid audited financial report for the year ended 31 December 2019
Safeguarding – supplemental annex to Unitaid wrongdoing guidelines
Disease Narrative for hepatitis C
Disease narrative for tuberculosis
Disease Narrative for malaria
Unitaid’s climate and health strategy 2023-2027
Unitaid’s investment case 2023-2027, executive summary
Unitaid’s investment case 2023-2027
Unitaid Strategy 2023-2027
Maternal and newborn health
Women’s and children’s health
Equitable access to therapeutics for pandemic preparedness and response
Overview of mpox antivirals and diagnostics landscape
Next generation pulse oximeters technology and market landscape
Malaria diagnostics market and technology landscape
Landscape of innovative tools and delivery strategies for eliminating vertical transmission of HIV, syphilis, hepatitis B, and chagas in endemic areas
Multipurpose prevention technologies: Technology landscape and potential for low- and middle-income countries
Screening and treatment for Chagas disease – technology and market landscape
Biomarkers for acute febrile illness at the point-of-care in low-resource settings. Technical working session. Meeting pre-reads
Unitaid and the Government of Spain
About Unitaid (Saving lives faster)
Unitaid and the UK Government
Unitaid audited financial report for the year ended 31 December 2023
Partnership report: Unitaid and the Global Fund to Fight AIDS, Tuberculosis and Malaria
Unitaid audited financial report for the year ended 31 December 2022
Impact story: Improving use of tuberculosis diagnostics
Impact story: Improving severe malaria outcomes
Impact story: Accelerating access to seasonal malaria chemoprevention
Impact story: HIV Self-Testing
Impact story: Improved treatment for HIV: Dolutegravir
Impact story: Early-infant diagnosis of HIV using point-of-care technologies
Impact story: Medicines Patent Pool
Impact story: Childhood tuberculosis
